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Kido, Shinsuke, Naoyuki Hasebe, Yoshinao Ishii, and Ken-
jiro Kikuchi. Tachycardia-induced myocardial ischemia and dia-
stolic dysfunction potentiate secretion of ANP, not BNP, in hy-
pertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 290:
H1064 –H1070, 2006. First published September 19, 2005;
doi:10.1152/ajpheart.00110.2005.—The aim of this study was to
investigate what factor determines tachycardia-induced secretion of
atrial and brain natriuretic peptides (ANP and BNP, respectively) in
patients with hypertrophic cardiomyopathy (HCM). HCM patients
with normal left ventricular (LV) systolic function and intact coronary
artery (n  22) underwent rapid atrial pacing test. The cardiac
secretion of ANP and BNP and the lactate extraction ratio (LER) were
evaluated by using blood samples from the coronary sinus and aorta.
LV end-diastolic pressure (LVEDP) and the time constant of LV
relaxation of tau were measured by a catheter-tip transducer. These
parameters were compared with normal controls (n  8). HCM
patients were divided into obstructive (HOCM) and nonobstructive
(HNCM) groups. The cardiac secretion of ANP was significantly
increased by rapid pacing in HOCM from 384  101 to 1,268  334
pg/ml (P  0.05); however, it was not significant in control and
HNCM groups. In contrast, the cardiac secretion of BNP was fairly
constant and rather significantly decreased in HCM (P  0.01). The
cardiac ANP secretion was significantly correlated with changes in
LER (r  0.57, P  0.01) and tau (r  0.73, P  0.001) in HCM
patients. Tachycardia potentiates the cardiac secretion of ANP, not
BNP, in patients with HCM, particularly when it induces myocardial
ischemia and LV diastolic dysfunction.
left ventricular outflow tract obstruction; lactate extraction ratio; left
ventricular diastolic function; cardiac event; atrial and brain natri-
uretic peptides
THE CLINICAL SIGNIFICANCE of natriuretic peptides has been
widely accepted in the management of heart failure. The
plasma levels of brain natriuretic peptide (BNP) correlate well
with the clinical severity of heart failure and hypertrophy (2, 8,
14). BNP is secreted mainly from the ventricle, whereas atrial
natriuretic peptide (ANP) is produced and secreted not only
from the atrium but from the ventricle in the hypertrophied
heart (4, 23, 32). ANP synthesis is also enhanced in patients
with heart failure (21, 36); however, the plasma ANP levels
fluctuate more easily compared with BNP levels.
The plasma levels of natriuretic peptides have been reported
to be increased despite the intact contractile function of the left
ventricle (LV) in patients with hypertrophic cardiomyopathy
(HCM). The hypertrophied heart is prone to complicate with
diastolic dysfunction (35). Tachycardia induces heart failure in
patients with hypertrophied LV because diastolic dysfunction
can be aggravated by shortening of diastolic phase (1, 12, 31).
Tachycardia is also prone to induce myocardial ischemia even
in HCM with angiographically normal coronary arteries. Al-
though rapid pacing linearly increases coronary flow in control
subjects, it decreases coronary flow at a high pacing rate in
HCM patients (3). Tachycardia may reduce coronary perfu-
sion, induce myocardial ischemia, and worsen diastolic relax-
ation in HCM. The vicious circle of myocardial ischemia and
diastolic dysfunction potentially enhances the production and
secretion of natriuretic peptides in HCM. However, the re-
sponses to tachycardia must be different in regulatory ANP
secretion and in constitutive BNP secretion.
Few reports have demonstrated the mechanistic consequence
of natriuretic peptide secretion and the tachycardia-induced
hemodynamic derangement in HCM. The present investigation
was designed to study the mechanism of tachycardia-induced
secretion of natriuretic peptides in terms of myocardial ische-
mia and left ventricular (LV) diastolic dysfunction in HCM.
METHODS
Subjects. This study was conducted in accordance with the guide-
line of the ethical committee of Asahikawa Medical College. The
purpose and potential risks of the study were fully explained to all
subjects before they gave their voluntary written informed consent to
participate.
Twenty-two patients with HCM were enrolled in the present study
(13 men, 9 women; mean age 53  11 yr). The diagnosis of HCM was
made by the findings of an electrocardiogram, echocardiogram, car-
diac catheterization, angiography, and myocardial biopsy. Exclusion
criteria for patients were the following: 1) New York Heart Associ-
ation functional class III or IV, 2) LV ejection fraction under 60% or
LV segmental asynergy in left ventriculogram, 3) mitral regurgitation
of Seller’s II or over, 4) organic stenosis in coronary arteriogram, 5)
chronic atrial fibrillation, 6) other organic heart disease including
valvular heart disease and bundle branch block, and 7) hypertension or
renal dysfunction. In the present study, 7 patients with intraventricular
pressure gradient of 20 mmHg or over were defined as hypertrophic
obstructive cardiomyopathy (HOCM), and the rest of 15 patients were
defined as hypertrophic nonobstructive cardiomyopathy (HNCM).
Eight patients with chest pain syndrome, who were admitted because
of chest pain but had been ruled out angina pectoris, were enrolled as
controls (5 men, 3 women; mean age 56  3 yr). All the patients
studied have been periodically followed after the rapid pacing study.
The major cardiac events, including admission for heart failure,
serious arrhythmia attack, syncope, and worsening of chest pain as
well as cardiac death were reported and registered.
Rapid right atrial pacing test. All the drugs that potentially affect
hemodynamics were discontinued at least 1 wk before the rapid
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pacing test. Right atrial pacing was initiated at a rate of 90 beats/min.
The pacing rate was stepwise increased by 20 beats/min every 3 min
up to the maximum rate of 150 beats/min. In case atrioventricular
block appeared during the total of 12 min of pacing, the achievable
maximum pacing rate was maintained.
Hemodynamic studies. A 6-Fr pigtail angiographic high-fidelity,
micromanometer-tipped catheter (Millar Instruments) was retro-
gradely advanced into the LV through the femoral artery. The LV
systolic pressure (LVSP) and LV end-diastolic pressure (LVEDP)
were continuously monitored. To investigate the LV diastolic func-
tion, the peak negative rate of change of LV diastolic pressure (dP/dt)
and the time constant of isovolemic relaxation of LV (tau) was used
(22). Tau was calculated using a modified method described by Raff
and Glantz (28). We continuously recorded 12 leads of the electro-
cardiogram throughout the study. According to the electrocardiogram
changes during pacing, we divided all patients with HCM into two
groups: the ST-D() group consisted of patients who showed addi-
tional ST segment depression 0.1 mV or over on two or more leads of
12-lead electrocardiogram, and the ST-D() group consisted of pa-
tients who did not show additional significant ST segment depression
by rapid pacing.
Cardiac secretion of natriuretic peptides and lactate extraction
ratio. A 6-Fr Goodale-Lubin catheter was advanced into coronary
sinus (CS) through the subclabian vein to obtain CS blood samples.
Blood samples before and at the end of rapid pacing test for 12 min
were obtained from CS and from the aorta (Ao) simultaneously via
pigtail catheter. Plasma ANP concentration was measured with a
specific immunoradiometric assay for -human ANP (Shionoria ANP
kit). Plasma BNP concentration was measured with a specific immu-
noradiometric assay for human BNP (Shionoria BNP kit). The cross
reactivity of the ANP kit with human BNP and the BNP kit with
-human ANP were 0.001% on a molar basis, respectively (36).
Cardiac secretion of ANP and BNP was determined as the difference
of those levels in between CS and Ao. Lactate levels were measured
using enzymatic method (Determiner LA, Kyowa Medics). The lac-
tate extraction rate (LER) was calculated as:
LER  100LACao LACcs/LACao
where LACAo is the lactate level in Ao and LACcs is the lactate level
in CS.
Echocardiographic data. Echocardiograms were performed using
high-quality echocardiographic equipment (SSD 875, Aloka). Mea-
surements were taken from the parasternal long- or short-axis M-
mode or two-dimensional views obtained using 2.5- and 3.5-MHz
transducers. Left atrial dimension (LAD), interventricular septal
thickness (IVST), LV posterior wall thickness (PWT), LV end-
diastolic dimension (LVDd), and end-systolic dimension (LVSd) were
measured. The sum of IVST and PWT was defined as LV wall
thickness. LV mass (LVM) was calculated by the method of Devereux
and Reichek (5) as follows:
LVM in g 1.04	LVDd IVST PWT3 LVDd3
 14
which was divided by body surface area to determine LVM index
[LVMI (g/m2)].
Statistics. All values were expressed as means  SE. Values
among three groups were compared by one-way analysis of variance
(ANOVA), and the unpaired Student’s t-test or 2-test was used for
comparison between two groups. The paired t-test was used to analyze
difference between serial samples from the same group of patients.
The two variable linear regression estimates were used for purposes of
correlation. Statistical significance was defined as P  0.05.
RESULTS
Patient characteristics and echocardiographic findings.
There were no significant differences in age and gender be-
tween control and HCM patients. (Table 1).
LV wall thickness and LVMI were greater in HCM patients
compared with control group; however, there were no signif-
icant differences in these indexes between HNCM and HOCM
groups. The mean intra-LV pressure gradient of HOCM was
56.0  15.6 mmHg. There were no significant differences in
LAD between control and HCM patients (Table 1).
Hemodynamics at the baseline and after pacing. The
changes in hemodynamics at the baseline and 1 min after
pacing were summarized in Table 2. There were no significant
differences in heart rate (HR) between the control group and
HCM patients. LVSP was significantly greater in the HOCM
compared with control and HNCM patients before and after
pacing. The maximum achievable pacing rate of total HCM
patients was significantly higher compared with the control
group (P  0.05); however, there were no significant differ-
ences between HNCM and HOCM groups. HR was rapidly
recovered to the baseline level in the control group at 1 min
after pacing. In contrast, HR still remained at a significantly
higher level in HCM groups at 1 min after pacing. LVEDP at
the baseline and after pacing was significantly higher in HCM
patients compared with the control group. LVEDP was not
significantly affected by pacing in the control group; however,
LVEDP significantly increased in total HCM patients (P 
0.05). Peak pressure change (dP/dt) was significantly smaller
in both HNCM and HOCM groups compared with the control
group at the baseline as well as after pacing. Tau in HCM
patients was significantly greater at the baseline and after
pacing compared with those in the control group. The induc-
tion of chest pain in HOCM was 100%, which was signifi-
cantly higher compared with 12.5% in the control (P  0.01)
and 60% in HNCM (P  0.05) groups (Table 2).
Changes in cardiac lactate production. In the control group,
LER was not significantly affected by pacing. In contrast, LER
was significantly decreased after pacing in total HCM patients.
The changes in LER (LER, LER after pacing  LER at the
baseline) were significantly greater in HNCM and HOCM
groups compared with control group (Table 2).
Changes in cardiac secretion of ANP and BNP. The cardiac
secretion of ANP and BNP was well correlated with the levels
in aortic as well as CS blood samples. In the control group, the
cardiac secretion of ANP was slightly, but not significantly,
increased by rapid pacing (baseline: 255  119 pg/ml, pacing:
Table 1. Patient characteristics
Control
HCM
Total HNCM HOCM
No. of cases 8 22 15 7
Age, yr 563 542 543 555
Male/female 5/3 13/9 10/5 3/4
Echocardiogram
LAD, mm 384 401 392 413
IVST, mm 91 181† 182† 182†
IVST  PWT, mm 182 281† 282† 292†
LVMI, g/m2 1027 19913† 19316† 21123†
Left ventriculogram
LVEF, % 703 771* 772* 772*
Values are numbers or means  SE. HOCM, hypertrophic obstructive
cardiomyopathy; HNCM, hypertrophic nonobstructive cardiomyopathy; LAD,
left atrial dimension; IVST, intraventricular septal thickness; PWT, posterior
wall thickness; LVMI, left ventricular (LV) mass index; LVEF, LV ejection
fraction. *P  0.05; †P  0.01 vs. Control.
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314  74 pg/ml) (Fig. 1, Table 2). In patients with HCM, the
cardiac secretion of ANP was significantly increased by rapid
pacing (baseline: 374  65 pg/ml, pacing: 700  139 pg/ml,
P  0.05) and was significantly greater compared with the
control group (P  0.05). The increase in cardiac secretion of
ANP was not significant in HNCM but was significant and
marked in HOCM patients (baseline: 384  101 pg/ml, pacing:
1,268  334 pg/ml, P  0.05) (Fig. 1, Table 2).
In contrast, the cardiac secretion of BNP was not increased
in all groups, but it was rather significantly decreased in HCM
patients by rapid pacing (baseline: 103  43 pg/ml, pacing:
66  31 pg/ml, P  0.05) (Fig. 1, Table 2).
Comparison between ST-D () and ST-D () groups. HCM
patients were divided into ST-D () and ST-D () groups.
There were no significant differences in HR, LVSP, LVEDP,
and peak negative dP/dt between ST-D () and ST-D ()
groups. The ST-D () group included significantly greater
numbers of HOCM compared with the ST-D () (P  0.01)
(Table 3). The incidence of resting ECG abnormalities was not
significantly different between the groups of ST-D () and
ST-D () patients. Tau in the ST-D () group was signifi-
cantly greater at the baseline and after pacing compared with
those in the ST-D () group. The induction of chest pain in
ST-D () was 100%, which was significantly higher compared
with 50% in the ST-D () group (P  0.01, Table 3).
Whereas LER was significantly decreased after pacing in
both ST-D () and ST-D () groups, LER was significantly
greater in the ST-D () group compared with the ST-D ()
group (Table 3). The LER of HCM patients were signifi-
cantly correlated with the changes in ST level (ST: ST level
after pacing  ST level at the baseline in the lead showing the
maximal change) [r  0.64, P  0.01 (data not shown)]. Thus
we considered that additional ST depression by rapid atrial
pacing suggested myocardial ischemia in HCM patients.
The cardiac secretion of ANP in the ST-D () group was not
significantly affected by rapid pacing. In contrast, the cardiac
secretion of ANP in the ST-D () group was significantly
increased and was significantly greater compared with the
ST-D () group at the peak pacing (P  0.05, Table 3).
Table 2. Changes in parameters by rapid atrial pacing
HCM
Control Total HNCM HOCM
Baseline Pacing Baseline Pacing Baseline Pacing Baseline Pacing
HR, beats/min 614 624 662 753a,f 673 754a,f 653 766
LVSP, mmHg 1285 1285 1509a 1537b 1295 1366 19419a,c 1908b,d
LVEDP, mmHg 81 71 141b 182b,e 131b 172b 163a 225a
-dP/dt, mmHg/s 1,73360 1,70851 1,20652b 1,29358b,e 1,18855b 1,27555b 1,246112b 1,323139a
Tau, ms 432 393 511b 513a 491a 472a 542b 609
maxPR, beats/min 1335 1443a 1444 1454
Chest pain 1/8 16/22b 9/15a 7/7b,c
ST-D ()/() 0/8 10/12a 4/11 6/1b,d
LER (%) 89 174a 134a 238a
ANP Ao 339 7318f 8414b 20938b,f 7215a 13931f 11030a 36076b,f
ANP CS 28749 38776 45770 909162a,f 44091 57491 494109 1,628349a,c,f
ANP, pg/ml 5974 326124 6673 884258a,d
BNP Ao 155 177 6919a 9225b,e 6421a 6823a 8141 14460
BNP CS 3111 3111 17247b 15745a 13040a 11132a 263120 257124
BNP, pg/ml 22 3716a 249 6828
Values are numbers or means  SE. HR, heart rate; LVSP, LV systolic pressure; LVEDP, LV end-diastolic pressure; maxPR, maximum pacing rate; -dP/dt,
minimum rate of change of LV diastolic pressure; Tau, time constant; Chest pain, induction of chest pain; ST-D ()/(), patients with/without additional ST
segment depression; LER, changes in lactate extraction ratio; Ao, aorta; CS, coronary sinus; ANP and BNP, the changes in cardiac secretion of ANP and
BNP respectively. aP  0.05 vs. control; bP  0.01 vs. control; cP  0.05 vs. HNCM; dP  0.01 vs. HNCM; eP  0.05 vs. baseline; fP  0.01 vs. baseline.
Fig. 1. Cardiac secretion of atrial natriuretic papertide (ANP) (top) after
pacing (filled bar) was not significantly increased in control from the baseline
(open bar) but was significantly increased by rapid pacing in hypertrophic
cardiomyopathy (HCM), particularly in obstructive HCM (HOCM) patients. In
contrast, the cardiac secretion of brain natriuretic peptide (BNP) (bottom) was
not increased in all groups but rather significantly decreased in HCM patients
by rapid pacing. *P  0.05; **P  0.01.
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In contrast, the cardiac secretion of BNP was not increased
but rather decreased in both groups, particularly in the ST-D
() by rapid pacing (P  0.01, Table 3).
Cardiac secretion of ANP and its related factors in HCM.
The cardiac secretion of ANP was not significantly correlated
with hemodynamic and echocardiographic variables at the
baseline in HCM. In contrast, those at the peak pacing were
significantly correlated with tau (r  0.77, P  0.001). The
ANP was not significantly correlated with LVEDP but
significantly correlated with tau (r  0.73, P  0.001) and
with LER (r 0.57, P  0.01) (Fig. 2). The LER was not
significantly correlated with tau at the baseline; however, it
was significantly correlated with tau after pacing (r  0.49,
P  0.05) and tau (r  0.48, P  0.05) (Fig. 3).
Clinical consequence. All the patients studied have been
followed up for 6.5  0.2 yr after the rapid pacing study. Five
major cardiovascular events occurred, including sudden death,
cerebral infarction, renal infarction, syncopal attack due to
arrhythmia, and admission for congestive heart failure. The
incidence of major cardiovascular events was significantly
greater in patients who showed greater cardiac secretion of
ANP, i.e., 80% in HCM patients showing ANP  368 pg/dl
(the median of cardiac secretion of ANP) and 7.1% in HCM
patients showing ANP  368 pg/ml. Inversely, the cardiac
secretion of ANP in the patients suffered major cardiovascular
events was significantly greater compared with that in the
event-free patients (Fig. 4).
DISCUSSION
The present study demonstrated that the cardiac secretion of
ANP, not BNP, was enhanced during tachycardia and was
significantly correlated with tachycardia-induced hemody-
namic derangement, particularly myocardial ischemia and LV
diastolic dysfunction in patients with HCM.
Tachycardia is a crucial factor for deterioration of LV
diastolic dysfunction in the patients with LV hypertrophy (1,
3). Tachycardia is also a stimulation to induce myocardial
ischemia. It has been reported that myocardial ischemia per se
enhances secretion of ANP in clinical as well as experimental
studies (11, 13, 20, 33). Myocardial ischemia has been repeat-
edly related to a pathophysiological background of HCM (3, 6,
27, 30, 34). Several possible mechanisms for myocardial is-
chemia of HCM include the reduced coronary blood flow per
unit of LV mass (27), the reduced coronary flow reserve by
impaired LV relaxation, and coronary endothelial dysfunction
(3, 30). Tachycardia-induced myocardial ischemia is a poten-
tial determinant of clinical severity in patients with HCM. It
was noteworthy that the HR 1 min after the rapid atrial pacing
was significantly higher in HCM patients compared with con-
trol despite the equivalent baseline HR, suggesting a prolonged
recovery from the stress of tachycardia and prolonged effects
of myocardial ischemia in chronic LV hypertrophy (9).
Tachycardia is a potent stimulation for ANP secretion, as
reported in tachyarrhythmia (29) and in a rapid pacing study
(24). In contrast, the cardiac secretion of BNP was fairly
Table 3. Comparison between ST-D () and
ST-D () group
HCM
ST-D () (n  12) ST-D () (n  10)
Baseline Pacing Baseline Pacing
HR, beats/min 683 774‡ 642 744§
LVSP, mmHg 1438 1468 15914 16211
LVEDP, mmHg 132 172 162 203
-dP/dt, mmHg/s 1,28155 1,30559 1,11777 1,277104
Tau, ms 481 458 541† 586*
max PR, beats/min 1455 1485
Chest pain 6/12 10/10
HNCM/HOCM 11/1 4/6*
LER, % 93 255*
ANP, pg/ml 356100 40497 41977 1,058225*‡
ANP, pg/ml 48102 639193*
BNP, pg/ml 6423 4613 144.255.9 87.542.3§
BNP, pg/ml 1814 5716
Values are numbers or means  SE. HR, heart rate; LVSP, left ventricular
systolic pressure; LVEDP, left ventricular end-diastolic pressure; maxPR,
maximum pacing rate; -dP/dt, minimum rate of change of left ventricular
diastolic pressure; Tau, time constant; HOCM, hypertrophic obstructive car-
diomyopathy; HNCM, hypertrophic nonobstructive cardiomyopathy; ANP and
ANP, cardiac secretion and its changes of ANP; BNP and BNP, cardiac
secretion and its changes of BNP; LER, changes in lactate extraction ratio,
*P  0.05 vs. ST-D (); †P  0.01 vs. ST-D (); ‡P  0.05 vs. baseline;
§P  0.01 vs. baseline.
Fig. 2. Change in ANP (ANP) during rapid pacing was
significantly and positively correlated with tau, an index
of left ventricular (LV) diastolic dysfunction (r  0.73,
P  0.001, left) and negatively correlated with change in
lactate extraction ratio (LER), a negative index of myo-
cardial ischemia (r  0.57, P  0.01, right) in HCM.
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constant during rapid pacing, rather decreasing in the present
study. ANP is synthesized and stored in both the atria and
ventricles, whereas BNP is synthesized and stored mainly in
ventricles (36). ANP is stored in granules and released episod-
ically in response to cardiac stress. In contrast, BNP is synthe-
sized as preproBNP in bursts (14). Increase of coronary blood
flow during rapid pacing may dilute plasma levels of natriuretic
peptides. The balance between the enhanced cardiac secretion
of natriuretic peptides and the diluting effects of increased
coronary blood flow appeared to be positive for ANP and
negative for BNP.
In the present study, the rapid atrial pacing itself did not
enhance ANP secretion in control nor in HNCM of HCM,
which mainly included patients lacking significant ST depres-
sion on electrocardiogram. The additional ST depression at
tachycardia is believed to reflect myocardial ischemia in pa-
tients with HCM (25). The higher incidence of chest pain and
greater production of lactate in the present study indicated
more severe myocardial ischemia in HCM patients with addi-
tional significant ST depression. More importantly, the secre-
tion of ANP was enhanced only in HCM patients with signif-
icant myocardial ischemia, suggesting a key role of myocardial
ischemia in augmentation of ANP secretion in HCM. In pa-
tients with angina pectoris, ANP secretion has been reported to
be increased with induction of myocardial ischemia by exercise
(20), dipyridamole (13), and percutaneous transluminal coro-
nary angioplasty (11). One plausible mechanism is that the
elevated left atrial pressure caused by myocardial ischemia
stimulates secretion of ANP. On the contrary, Uusimaa et al.
(33) have reported that myocardial ischemia directly stimulates
secretion of ANP from the ventricle via energy metabolic
mechanism. The secretion of ANP in HCM was closely cor-
related with tau, and the increase in ANP secretion was not
significantly correlated with the increase in LVEDP but with
the lactate production during rapid pacing. Moreover, there
was no significant relationship between the left atrial dimen-
sion and the cardiac secretion of ANP during rapid atrial
pacing (data not shown). These findings suggest that the
enhanced secretion of ANP in HCM may be attributable to
myocardial ischemia itself rather than hemodynamic overload
to the left atrium. However, we could not definitely rule out an
impact of increased left atrial stress and elevated LVEDP on
enhanced secretion of ANP in HCM, particularly in HOCM
patients and patients with ischemia during rapid atrial pacing.
Masuyama et al. (19) reported that LV diastolic dysfunction
could induce myocardial ischemia during tachycardia in pa-
tients without significant coronary stenosis, which was indi-
cated by a significant correlation between the prolonged tau
and impaired coronary flow reserve during tachycardia. Myo-
cardial ischemia prolongs tau vice versa (7). In the present
study, tau after pacing and changes in tau were significantly
correlated with lactate production during tachycardia. These
findings suggest that myocardial ischemia associated with LV
diastolic dysfunction may directly stimulate secretion of ANP
in patients with HCM during tachycardia.
Derchi et al. (4) reported that the plasma ANP level was
significantly correlated with the morphological severity in
HCM patients including severe heart failure. Takemura et al.
(32) reported that the content of ANP in ventricular myocytes
was dependent on the histological severity of hypertrophy but
not dependent on the baseline hemodynamic variables in HCM
patients. In the present study, we have recruited HCM patients
with stable hemodynamic condition and found that the param-
eters of echocardiography were not significantly correlated
with the secretion of ANP, suggesting that the morphological
severity of hypertrophy does not seem to be the sole determi-
nant of the baseline secretion of ANP. It was significantly
correlated with tau after pacing, indicating that the more LV
diastolic function was impaired, the more secretion of ANP
was augmented at tachycardia. ANP is a potent compensatory
factor for hemodynamic stress in hypertrophied heart, and the
secretion of ANP is determined by the grade of stress and
stiffness of LV in hypertrophied heart (10).
Fig. 3. LER was significantly and negatively correlated with
tau after pacing (r  0.49, P  0.05, left) and tau (r 
0.48, P  0.05, right) in HCM.
Fig. 4. Cardiac secretion of ANP was significantly greater in the subgroups of
patients with major cardiovascular events.
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The clinical outcome of HCM is known to be highly variable
(16). In the present study, HOCM patients, particularly those
who demonstrated significant myocardial ischemia during
rapid pacing showed more serious outcome including one
sudden death. Recent studies have demonstrated that outflow
tract obstruction is independently associated with an increased
risk of events in HCM (15, 17, 18). We believe that the
tachycardia-induced vicious circle of myocardial ischemia and
left ventricular diastolic dysfunction aggravate clinical out-
come of patients with HCM. The augmented secretion of ANP
during tachycardia, which is attributable to myocardial ische-
mia rather than hemodynamic overload, may predict serious
outcome in patients with HCM.
Study limitations. In the present study, we did not measure
the coronary blood flow. An inappropriate increase of coronary
blood flow in HCM patients shown by Cannon et al. (3) would
have been able to increase ANP concentration in the coronary
sinus, despite similar ANP production. However, the amplitude
of variation in coronary blood flow shown by Cannon et al. is
not sufficient to affect the present findings. Furthermore, it
could not explain the differences between ANP and BNP. The
balance between the cardiac secretion of natriuretic peptides
and the effects of coronary blood flow was positive to the ANP
levels and negative to the BNP levels.
We monitored only the short-term changes in the cardiac
secretion of natriuretic peptides. The longer term changes in
the cardiac secretion of both peptides must be different. BNP is
also synthesized in response to the stress of tachycardia,
myocardial ischemia, and cardiac dysfunction; however, its
cardiac secretion does not seem to be episodic as we demon-
strated in the present study.
In conclusion, the cardiac secretion of ANP, not BNP, was
enhanced during tachycardia in patients with HCM. The car-
diac secretion of ANP was significantly correlated with the
degree of myocardial ischemia and LV diastolic dysfunction.
This positive relationship may facilitate a vicious circle of
tachycardia and poor clinical outcome in patients with HCM.
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